Market Cap 5.45M
Revenue (ttm) 2.00M
Net Income (ttm) -59.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,980.50%
Debt to Equity Ratio 0.00
Volume 13,600
Avg Vol 53,030
Day's Range N/A - N/A
Shares Out 1.66M
Stochastic %K 14%
Beta 0.76
Analysts Hold
Price Target $10.00

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcino...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 558 0708
Fax: 858 558 0709
Address:
11085 Torreyana Road, San Diego, United States
SDBiotechInvestor
SDBiotechInvestor Jul. 31 at 2:26 PM
$HOWL objectively horrible update today. Long road ahead and TCE platform likely not worth much e.g. $BCAB. Can see this heading back to mid 0.30s.
1 · Reply
JA1950
JA1950 Jul. 31 at 10:59 AM
$BCAB Not Financial Advice / Do Your Own Research. FRIDAY PART 1: As follow-up to yesterday, wanted to add a couple of upcoming milestone dates and perspective. (1) BCAB has been compliant with all SEC filings in 2026. (2) Given their annual shareholder meeting was only two weeks ago, and in that meeting it was voted to retain Ernst & Young for another year, and that there have been no subsequent filings regarding their auditor, I would expect the 10Q for 2Q to be filed on or before Aug 15th. (3) The 10Q should reveal cash position as of June 30, 2026, which will include the May 15th payment from Context of $4.5M. It should also note if Context made the $2.5M payment due August 1st. Combined, we should be able to get a better sense of the monthly burn rate with the reduced workforce, etc. I have it as $600-700K now, which means that if they started Q2 with $2M, added $6.5M, they should have approx $5M as of Aug 31 (assuming the higher $700K/mos burn).
1 · Reply
JA1950
JA1950 Jul. 30 at 6:40 PM
$BCAB DYOR/NFA. PART 1: While recognizing this is a highly speculative stock, I am extremely bullish near term for the company based on the following: (1) Market Cap is $5.7M (2) Context Thereapuetics just paid total consideration of $18.5M for a pre-clinical that they had a license to since mid-2025. This means that after doing rigorous diligence on a drug from the BCAB's CAB platform, they paid more than 3x the current market cap for a drug that hadn't yet entered Phase 1. (3) BCAB is a holding company for substantial assets currently being marketed by Tungsten (4) a sale of a single Phase I asset for $25M (which would be on the low end given the current market, would wipe out 21M of accounts payable and add to their current cash balance of approx $3-5M, likley arming the company with $5-7M entering 4Q.
1 · Reply
Digfog
Digfog Jul. 30 at 1:32 AM
$BCAB quarterly coming within a week or two, time to expect the influx of pretender pumper groups to migrate here hoping to make some Pennies to pay their water bills. I remember not too long ago when actual analysts joined the boys on their call, then they were lied to and that’s that they ran. Now we got jay and some fools that fell into their jobs giving zero info at all. Maybe this time will be different? I consider toilet paper more valuable than my 8142 shares at this point though (to be fair my TP is triple ply) so I’m not holding my breath. ✌️
0 · Reply
biovaluable
biovaluable Jul. 30 at 12:42 AM
$BCAB nice short position at 3.6! go under $3!!! chinese J scam!
0 · Reply
biovaluable
biovaluable Jul. 22 at 11:52 PM
$BCAB nice short position at 0.4$! 15000$ gain!
0 · Reply
biovaluable
biovaluable Jul. 21 at 2:27 AM
$BCAB chinese scam stock. FXXX jay
0 · Reply
Moonlightcat
Moonlightcat Jul. 17 at 11:39 AM
$BCAB do not buy this stock. It's a fraud. There is a possibility that ceo and wife will be charged by Criminal and manipulated behaviour. Stock will be halted and in the end cancelled
1 · Reply
focafoca99
focafoca99 Jul. 16 at 8:27 PM
$BCAB recorded its annual meeting results, approving two new directors and ratifying Ernst & Young as auditor.
1 · Reply
pankooo
pankooo Jul. 16 at 2:15 PM
$BCAB Today is the general meeting.
0 · Reply
Latest News on BCAB
BioAtla Proxy statement: Proxy filing

Jun 3, 2026, 8:00 AM EDT - 2 months ago

BioAtla Proxy statement: Proxy filing


BioAtla Proxy statement: Proxy filing

Jun 3, 2026, 8:00 AM EDT - 2 months ago

BioAtla Proxy statement: Proxy filing


BioAtla Quarterly report: Q1 2026

May 15, 2026, 4:00 PM EDT - 2 months ago

BioAtla Quarterly report: Q1 2026


BioAtla trading halted, news pending

2026-04-02T23:50:53.000Z - 4 months ago

BioAtla trading halted, news pending


BioAtla announces 50-for-1 share consolidation

2026-03-31T20:45:40.000Z - 4 months ago

BioAtla announces 50-for-1 share consolidation


BioAtla Announces Share Consolidation

Mar 31, 2026, 4:06 PM EDT - 4 months ago

BioAtla Announces Share Consolidation


BioAtla Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 4 months ago

BioAtla Annual report: Q4 2025


BioAtla Slides: Investor presentation

Mar 24, 2026, 8:00 AM EDT - 4 months ago

BioAtla Slides: Investor presentation


BioAtla Proxy statement: Proxy Filing

Mar 2, 2026, 7:00 AM EST - 5 months ago

BioAtla Proxy statement: Proxy Filing


BioAtla Proxy statement: Proxy Filing

Feb 11, 2026, 7:00 AM EST - 6 months ago

BioAtla Proxy statement: Proxy Filing


BioAtla Proxy statement: Proxy Filing

Jan 30, 2026, 7:00 AM EST - 6 months ago

BioAtla Proxy statement: Proxy Filing


BioAtla Registration statement: Registration Filing

Jan 16, 2026, 7:00 AM EST - 7 months ago

BioAtla Registration statement: Registration Filing


BioAtla Proxy statement: Proxy Filing

Jan 15, 2026, 7:00 AM EST - 7 months ago

BioAtla Proxy statement: Proxy Filing


BioAtla Proxy statement: Proxy Filing

Dec 31, 2025, 7:00 AM EST - 7 months ago

BioAtla Proxy statement: Proxy Filing


BioAtla Proxy statement: Proxy Filing

Dec 5, 2025, 7:00 AM EST - 8 months ago

BioAtla Proxy statement: Proxy Filing


BioAtla Proxy statement: Proxy Filing

Nov 24, 2025, 7:00 AM EST - 9 months ago

BioAtla Proxy statement: Proxy Filing


BioAtla Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

BioAtla Earnings Call Transcript: Q3 2025


BioAtla Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

BioAtla Quarterly report: Q3 2025


BioAtla Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

BioAtla Earnings release: Q3 2025


BioAtla Slides: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

BioAtla Slides: Q3 2025


BioAtla Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings Call Transcript: Q2 2025


BioAtla Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

BioAtla Quarterly report: Q2 2025


BioAtla Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings release: Q2 2025


BioAtla Slides: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

BioAtla Slides: Q2 2025


BioAtla Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings Call Transcript: Q1 2025


BioAtla Quarterly report: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

BioAtla Quarterly report: Q1 2025


BioAtla Earnings release: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings release: Q1 2025


BioAtla Registration statement: Registration Filing

May 6, 2025, 8:00 AM EDT - 1 year ago

BioAtla Registration statement: Registration Filing


BioAtla Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

BioAtla Proxy statement: Proxy Filing


BioAtla Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

BioAtla Proxy statement: Proxy Filing


BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 5:05 PM EDT - 1 year ago

BioAtla Cuts 30% of Jobs in Restructuring Effort


BioAtla Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings Call Transcript: Q4 2024


BioAtla Annual report: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

BioAtla Annual report: Q4 2024


BioAtla Earnings release: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings release: Q4 2024


BioAtla Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

BioAtla Earnings Call Transcript: Q3 2024


BioAtla Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

BioAtla Quarterly report: Q3 2024


BioAtla Earnings release: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

BioAtla Earnings release: Q3 2024


BioAtla Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings Call Transcript: Q2 2024


BioAtla Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

BioAtla Quarterly report: Q2 2024


BioAtla Earnings release: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings release: Q2 2024


BioAtla Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings Call Transcript: Q1 2024


BioAtla Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

BioAtla Quarterly report: Q1 2024


BioAtla Earnings release: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings release: Q1 2024


BioAtla Transcript: The Citizens JMP Life Sciences Conference

May 13, 2024, 9:30 AM EDT - 2 years ago

BioAtla Transcript: The Citizens JMP Life Sciences Conference


BioAtla Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

BioAtla Proxy statement: Proxy Filing


BioAtla Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

BioAtla Proxy statement: Proxy Filing


BioAtla Earnings Call Transcript: Q4 2023

Mar 26, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings Call Transcript: Q4 2023


BioAtla Annual report: Q4 2023

Mar 26, 2024, 4:30 PM EDT - 2 years ago

BioAtla Annual report: Q4 2023


BioAtla Earnings release: Q4 2023

Mar 26, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings release: Q4 2023


SDBiotechInvestor
SDBiotechInvestor Jul. 31 at 2:26 PM
$HOWL objectively horrible update today. Long road ahead and TCE platform likely not worth much e.g. $BCAB. Can see this heading back to mid 0.30s.
1 · Reply
JA1950
JA1950 Jul. 31 at 10:59 AM
$BCAB Not Financial Advice / Do Your Own Research. FRIDAY PART 1: As follow-up to yesterday, wanted to add a couple of upcoming milestone dates and perspective. (1) BCAB has been compliant with all SEC filings in 2026. (2) Given their annual shareholder meeting was only two weeks ago, and in that meeting it was voted to retain Ernst & Young for another year, and that there have been no subsequent filings regarding their auditor, I would expect the 10Q for 2Q to be filed on or before Aug 15th. (3) The 10Q should reveal cash position as of June 30, 2026, which will include the May 15th payment from Context of $4.5M. It should also note if Context made the $2.5M payment due August 1st. Combined, we should be able to get a better sense of the monthly burn rate with the reduced workforce, etc. I have it as $600-700K now, which means that if they started Q2 with $2M, added $6.5M, they should have approx $5M as of Aug 31 (assuming the higher $700K/mos burn).
1 · Reply
JA1950
JA1950 Jul. 30 at 6:40 PM
$BCAB DYOR/NFA. PART 1: While recognizing this is a highly speculative stock, I am extremely bullish near term for the company based on the following: (1) Market Cap is $5.7M (2) Context Thereapuetics just paid total consideration of $18.5M for a pre-clinical that they had a license to since mid-2025. This means that after doing rigorous diligence on a drug from the BCAB's CAB platform, they paid more than 3x the current market cap for a drug that hadn't yet entered Phase 1. (3) BCAB is a holding company for substantial assets currently being marketed by Tungsten (4) a sale of a single Phase I asset for $25M (which would be on the low end given the current market, would wipe out 21M of accounts payable and add to their current cash balance of approx $3-5M, likley arming the company with $5-7M entering 4Q.
1 · Reply
Digfog
Digfog Jul. 30 at 1:32 AM
$BCAB quarterly coming within a week or two, time to expect the influx of pretender pumper groups to migrate here hoping to make some Pennies to pay their water bills. I remember not too long ago when actual analysts joined the boys on their call, then they were lied to and that’s that they ran. Now we got jay and some fools that fell into their jobs giving zero info at all. Maybe this time will be different? I consider toilet paper more valuable than my 8142 shares at this point though (to be fair my TP is triple ply) so I’m not holding my breath. ✌️
0 · Reply
biovaluable
biovaluable Jul. 30 at 12:42 AM
$BCAB nice short position at 3.6! go under $3!!! chinese J scam!
0 · Reply
biovaluable
biovaluable Jul. 22 at 11:52 PM
$BCAB nice short position at 0.4$! 15000$ gain!
0 · Reply
biovaluable
biovaluable Jul. 21 at 2:27 AM
$BCAB chinese scam stock. FXXX jay
0 · Reply
Moonlightcat
Moonlightcat Jul. 17 at 11:39 AM
$BCAB do not buy this stock. It's a fraud. There is a possibility that ceo and wife will be charged by Criminal and manipulated behaviour. Stock will be halted and in the end cancelled
1 · Reply
focafoca99
focafoca99 Jul. 16 at 8:27 PM
$BCAB recorded its annual meeting results, approving two new directors and ratifying Ernst & Young as auditor.
1 · Reply
pankooo
pankooo Jul. 16 at 2:15 PM
$BCAB Today is the general meeting.
0 · Reply
Digfog
Digfog Jul. 16 at 5:50 AM
$BCAB so what’s the minimum they need to say or imply at meeting to keep the gravy train rolling? I’m gonna say they imply a “deal” by years end, that should keep it afloat for a bit.
1 · Reply
whateverhappenedthere
whateverhappenedthere Jul. 15 at 3:13 AM
$BCAB feels like we are firmly in the zombie bio stage, thank Jay
0 · Reply
biovaluable
biovaluable Jul. 10 at 7:48 AM
$BCAB nice short pisition at $4! it is easy game
0 · Reply
Moonlightcat
Moonlightcat Jul. 8 at 3:08 PM
$BCAB Get out.. company selling shares day to day. To keep the office running.
1 · Reply
Digfog
Digfog Jul. 7 at 7:49 PM
$BCAB just shut the doors already
0 · Reply
gregwiseman
gregwiseman Jul. 6 at 4:17 PM
$BCAB hope and wish from the bottom of my heart this mother fucker of market maker may use that 2k dollars for bying medicines and at the end hope he dies from the cancer . shit kind of human
0 · Reply
Moonlightcat
Moonlightcat Jul. 6 at 2:51 PM
$BCAB Great buy If you like to loose all your money. This is one big scam and are going to zero.
0 · Reply
BiotechValues
BiotechValues Jul. 6 at 1:39 PM
$BCAB interesting volume
0 · Reply
beentherebefor
beentherebefor Jul. 3 at 4:13 PM
$BCAB anyone see the poster/abstract from Esmo?
2 · Reply
HjalmarTheGreat
HjalmarTheGreat Jul. 2 at 6:18 PM
$BCAB https://academic.oup.com/oncolo/article/31/Supplement_1/oyag205.037/8712654
0 · Reply
biovaluable
biovaluable Jul. 1 at 7:30 AM
$BCAB chinese scam stock
1 · Reply